PSEN1
Presenilin-1
As of the edition of 20 October 2026, PSEN1 (presenilin-1, UniProt P49768) has 12 drugs tested at it and 14 companies on the list, 7 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49768
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 27
- Disease areas
- Cancer; Nervous system; Mental health; Blood and lymph; Immune system; Skin and connective tissue; Heart and blood vessels; Urinary and reproductive
- Registered trials of its drugs
- 109
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 6 |
| Stopped | 4 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| RG-4733 | Stopped | Phase 2 | none listed |
| Nirogacestat | Marketed | Phase 4 | Ends 2039 |
| Avagacestat | Stopped | Phase 2 | none listed |
| MK-0752 | Went quiet | Phase 4 | none listed |
| Osugacestat | Stopped | Phase 2 | none listed |
| Varegacestat | Active | Phase 3 | none listed |
| Tarenflurbil | Went quiet | Phase 3 | none listed |
| Begacestat | Went quiet | Phase 1 | none listed |
| Semagacestat | Went quiet | Phase 3 | none listed |
| CHF 5074 | Went quiet | Phase 1 | none listed |
| LY3056480 | Stopped | Phase 2 | none listed |
| NGP 555 | Went quiet | Phase 1 | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 1 |
| Engaged | 3 |
| Undetermined | 3 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Roche | Route A |
| Eli Lilly | Route A |
The other 11 companies at PSEN1
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at PSEN1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.